Updated: 15-Oct-26 09:08 ET
Co: IAM
Iambic Therapeutics (Nasdaq) | Phase 1 clinical biotech that uses its AI platform to design small molecule cancer drugs | Initial Shares: 9.4 M | Initial Range: $15.00-$17.00 | Priced On: 15-Oct-26, $16.00 | Opened: NA | Underwriters: Lead: J.P.Morgan, Jefferies, BofA Securities, Citigroup
Co: CTY
City Therapeutics (Nasdaq) | Clinical biotech company focused on developing RNA interference therapeutics to silence disease-relevant proteins | Initial Shares: 9.7M | Initial Range: $17.00-$19.00 | Priced On: NA | Opened: NA | Underwriters: Lead: Goldman Sachs, Jefferies, Stifel, Oppenheimer & Co.
There are no IPOs scheduled for this time period.
Co: SFPT
Safepoint Holdings (NYSE) | Provides specialty homeowners and commercial property insurance through managed reciprocal insurance exchanges and its own insurance carrier | Initial Shares: 16.7 M | Initial Range: $15.00-$17.00 | Priced On: NA | Opened: NA | Underwriters: Lead: Deutsche Bank Securities, Morgan Stanley
Co: TKVA
Salspera (Nasdaq) | Biotech developing engineered bacteria-based immunotherapies that deliver anti-cancer signals directly into solid tumors | Initial Shares: 5.7 M | Initial Range: $14.00-$16.00 | Priced On: NA | Opened: NA | Underwriters: Lead: Kingswood Capital Partners, LLC
There are no IPOs scheduled for this time period.